Live feed08:00:00·1801dPRReleasevia QuantisnowImmatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAMEByQuantisnow·Wall Street's wire, on your screen.IMTX· Immatics N.V.Health Care
